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ghere are only two mistakes one can make along
he path to truth: not going all the way, and not
tarting.
—Buddha (1)
his was in 1982. I was a clinical fellow in the
adsworth Veterans Administration Hospital,
os Angeles cardiovascular training program,
hen I was first exposed to myocardial contrast
chocardiography (MCE). I was enthralled by
mages obtained in a dog by Chuwa Tei who
as working at that time with Pravin Shah in
lliott Corday’s and Sam Meerbaum’s experi-
ental laboratory at Cedars-Sinai. Shortly
hereafter, I moved to Massachusetts General
ospital for a clinical and research fellowship.
y training in Boston was in both nuclear
ardiology and echocardiography under a car-
iovascular imaging training (T-32) program
hat was probably the first of its kind. I even
abbled in magnetic resonance imaging, which
as in its very early days. I chose to work on
CE as my major research project in echocar-
iography. The echocardiography section did
ot have its own experimental laboratory, and I
orked in the laboratory of Rob Okada. I had
ever been in an experimental laboratory be-
ore. Between Rob’s skilled technicians, Donna
utrario and Luis Guerrero, I learned complex
oronary surgery, including cannulation of the
eft main coronary artery, which was to become
rom the Division of Cardiovascular Medicine, Oregon Health and
cience University, Portland, Oregon. Dr. Kaul has consulted for
nd received grants from several companies manufacturing ultra-
ound contrast agents and equipment.m
anuscript received September 8, 2009; revised manuscript re-
eived October 5, 2009, accepted November 12, 2009.he mainstay of many future experiments.
rom Nat Pandian I learned how to image
pen-chest dogs, Ned Weyman tried his best
o teach me how to write, and John Newell
aught me biostatistics.
When I started doing these experiments,
eports of early MCE by Armstrong et al. (2)
nd Tei et al. (3) had already started to appear
howing the feasibility of using MCE for
ssessing myocardial perfusion. Andy Kemper
hen published some excellent reports while he
as working with Al Parisi at the Roxbury
eterans Administration Hospital (4,5). The
oncepts in MCE were probably ahead of their
ime. My initial interest was in defining area at
isk in vivo. At that time the experimental gold
tandard was post-mortem technetium autora-
iography. It soon became clear that with
CE we could measure risk area noninvasively
nd repeatedly (6). It also became clear that the
isk area was not static and dynamically
hanged based on systemic and coronary he-
odynamic conditions, including the coronary
riving pressure (7). Also, there was a poor
elationship between risk area size and hemo-
ynamics, particularly when risk area was
mall-to-moderate, suggesting that hemody-
amics poorly reflected the extent of myocar-
ial injury during acute coronary occlusion (8).
After completing my fellowship at Massachu-
etts General Hospital, I moved to the University
f Virginia (UVA), Charlottesville as a junior
aculty and was given an old ultrasound system
ATL Mark 3) in the corner of a communal
xperimental laboratory. Because of my back-
round in nuclear cardiology, I decided to
easure myocardial blood flow (MBF) with
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213CE. Until then I had used intracoronary injec-
ions of hand-agitated mixtures of Renografin and
aline, and needed to learn to make microbubbles
hat were small enough to pass through the capil-
aries. Steve Feinstein, who had been a fellow with
e in Los Angeles and had developed a method for
aking smaller bubbles by sonicating albumin so-
utions (9), came to UVA and taught us the
echnique. Mark Keller was the first fellow to work
ith me and studied the intravascular rheology of
hese bubbles in Brian Duling’s laboratory. He
emonstrated that these bubbles behaved like
rythrocytes within the microcirculation (10).
nanda Jayaweera subsequently showed that the
ransit time of these microbubbles through the
yocardium was similar to that of radiolabeled
rythrocytes during intracoronary injections at var-
ous flow conditions (11). After Jonathan Lindner
oined the laboratory, we observed that during
oncritical stenosis when MBF remained normal,
he myocardial transit times for a microbubble was
rolonged in proportion to the severity of the
tenosis because of the increase in coronary blood
olume caused by autoregulation (12). Therefore,
sing intracoronary injections, we could define the
resence and severity of coronary stenosis at rest by
easuring the myocardial transit times of micro-
ubbles. We were to revisit this novel finding a
ecade later.
By this time, we had also started performing human
tudies in the cardiac catheterization laboratory, and
eported the safety of intracoronary administration of
onicated Renografin and the feasibility of detecting a
tenosis in conjunction with coronary vasodilators.We
efined the value of MCE-derived collateral flow in
aintaining myocardial viability after myocardial in-
arction (MI) (13). This attracted attention from the
ardiology community because it provided for the
asis of better outcomes in patients with an open
nfarct-related artery in the presence of collateral-
ependent viable tissue in the infarct zone. A decade
ater, Matt Coggins, a medical student, showed that
ollateral flow could be measured using intravenous
dministration of microbubbles and that the extent of
ollateralization at the time of coronary occlusion
redicted the ultimate infarct size after reperfusion
14). Howard Leong-Poi went on to demonstrate that
ollateral flow was responsible for the disparity be-
ween the circumferential extent of regional dysfunc-
ion and infarct size and not tethering as previously
elieved (15). The collateral flow also explained the
isparity between the circumferential extent of re- eional dysfunction and perfusion defect during stress,
ending to the superiority of myocardial perfusion over
egional function for detecting coronary artery disease
CAD) during stress (15). Howard was also the first to
eport on the occurrence of a perfusion defect before
egional dysfunction during demand ischemia (16).
MCE gained further notoriety when Hiroshi Ito
sed it to define the no-reflow phenomenon in
cute MI; he showed that a sizeable proportion of
atients with Thrombolysis In Myocardial Infarc-
ion (TIMI) flow grade 3 after thrombolysis had
o-reflow, and that the degree and extent of no-
eflow defined outcome in these patients (17). At
he same time, Michael Ragosta, a fellow working
ith us, reported that the extent of microvascular
erfusion and not TIMI flow predicted functional
ecovery in recent MI with an open infarct-related
rtery (18). He won the American College of
ardiology Young Investigator Award for this
ork. Liza Villanueva performed a series of elegant
anine experiments to show that the no-reflow
henomenon was dynamic for hours after reflow,
ostly due to the hyperemic response during reper-
usion (19). It is now becoming clear that the best
ime for estimation of the no-reflow zone is at least
8 h after reperfusion, and that a coronary vasodi-
ator will need to be used if the no-reflow zone
and, hence, infarct size) is to be estimated earlier
fter the reperfusion. The hyperemia in the reper-
used bed is less than the perfusion in the normal
ed, and the relative hypoperfusion noted in the
eperfused bed during exogenously induced hyper-
mia predicts the ultimate no-reflow zone (20).
nterestingly, whereas the no-reflow zone at rest is
ynamic for several hours after reperfusion, it re-
ains constant during hyperemia and accurately
eflects the ultimate infarct size (19).
At about the same time, we, along with Bill
potnitz, had developed an interest in assessing
yocardial perfusion intraoperatively during coro-
ary artery bypass grafting (CABG). We validated
he methodology in canine experiments (10) fol-
owed by clinical studies in patients undergoing
ABG (21,22). Liza also devised complex experi-
ents to define the mechanism of myocardial
reservation during retrograde cardioplegia delivery
23). Despite its obvious advantages in patients
ndergoing CABG, MCE using this approach was
ot widely adopted because imaging was to be
erformed with a hand-held transducer and subse-
uently due to the arrival of more versatile trans-
sophageal echocardiographic technology.
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214Steve Feinstein’s technique of sonication was
dapted for the first commercially available ultra-
ound contrast agent, Albunex, for use as an intra-
enous agent for left ventricular (LV) cavity opaci-
cation (8). Although this agent produced excellent
yocardial opacification on intracoronary injec-
ions, it barely produced LV cavity opacification
fter intravenous administration. It became clear
hen that the air in the bubble diffused out and
issolved rapidly in blood, necessitating a new
eneration of ultrasound contrast agents. The
ewer agents either contained high molecular
eight gases that were not easily diffusible and
elatively insoluble in blood (such as sulfur
exafluoride, perfluorocarbons), or were made of
mpermeable shells (such as polymers). These
gents are now in clinical use, and several investi-
ators, such as Paul Grayburn, have demonstrated
he value of LV cavity opacification for improving
mage quality and accuracy of LV ejection fraction
easurements (24). Paul and others have also
emonstrated the feasibility of microbubble-based
ene delivery (25).
Despite the new contrast agents, myocardial opaci-
cation after intravenous injection had not been per-
ected for the following reasons. First, it is usually
ifficult to optimally differentiate the bubble signal
rom that of the myocardium, which has been partially
olved by the development of unique signal processing
lgorithms, such as harmonic imaging. Because the
ubbles resonate in an ultrasound field, they were
nduced to generate harmonic signals that could then
e captured using a broad-band transducer. At that
ime it was believed that tissue, being noncompress-
ble, did not generate harmonics. So it came as a
urprise when superior tissue images were obtained
sing this approach. Harmonic imaging has now
ecome the standard approach for obtaining B-mode
ltrasound images, and this technological advance is a
yproduct of MCE research. However, because tissue
as still visible on harmonic imaging, we developed
ff-line image processing tools to detect myocardial
pacification by the microbubbles (26). Jiri Sklenar, a
omputer scientist, is credited for developing algo-
ithms for image alignment, subtraction, color-coding,
nd display for accurate delineation of myocardial
pacification. This process, although very effective,
as tedious before the days of digital echocardiogra-
hy and involved many steps including digital conver-
ion of analog data. It was later superseded by clever
ignal processing algorithms that exploited the non-
inear signals emanating frommicrobubbles oscillating an an ultrasound field and negating those arising from
he tissue. These advances became possible by the
undamental discoveries of Peter Burns (27) and Nico
e Jong (28), who characterized the microbubble-
ltrasound interactions. Using digital image process-
ng, Villanueva was the first to demonstrate LV
yocardial opacification in dogs using right-sided
njection of concentrated Albunex (26).
The second reason for poor myocardial opacifi-
ation was the destruction of microbubbles with
ltrasound. This became apparent when Tom Por-
er accidentally stopped ultrasound transmission
uring a canine experiment at the University of
ebraska (29). On resuming ultrasound, he noted
xcellent myocardial opacification on the first few
rames before myocardial opacification again disap-
eared. Until then, imaging had been performed
sing relatively higher power, and the oscillating
ubbles were imploding from the ultrasound en-
rgy. It became apparent that decreasing the power
utput would allow better LV opacification. To-
ether with the newer signal processing algorithms,
yocardial opacification could be detected even
ith lower power output. Tom Porter became
nterested in MCE while he was a fellow at the
edical College of Virginia and visited UVA to
iscuss his projects and results with me. In addition
o becoming a leader in the field, he has also
ioneered other areas of microbubble-ultrasound
nteractions such as sonothrombolysis (30) and
rug/gene delivery (31).
With the development of the second-generation
ontrast agent containing a high molecular weight gas,
ptison, and harmonic imaging, we were eager to
emonstrate myocardial opacification in humans from
ntravenously administered microbubbles. However,
ince at that time both the ultrasound contrast agent
nd the imaging modality were ‘experimental’, we
ere not able to do so in the U.S. In collaboration
ith Roxy Senior at Northwick Park Hospital, Lon-
on, we studied 30 patients within a week who were
riginally scheduled for dipyridamole sestamibi-
ingle-photon emission computed tomography
SPECT) myocardial perfusion imaging. There was a
ood concordance between SPECT and image-
rocessed color-codedMCE images for reversible and
xed defects, and showed the feasibility of the clinical
se of intravenously administered ultrasound contrast
gent for the detection of CAD (32). This was Roxy’s
rst encounter with MCE, and he has since become a
eading exponent of this discipline. He has worked
xtensively on the value of MCE in the clinical
ssessment of myocardial viability.
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215Since individual MCE images represent a single
oint in time, myocardial acoustic intensity values
rom these images reflect myocardial blood volume
MBV) and not MBF. With the knowledge that
ltrasound can be used to destroy microbubbles, we
eveloped an approach for the quantification of MBF
hat measured both components of MBF-MBV and
BF velocity (33). At that time Kevin Wei had
oined my laboratory, and he worked extensively at
alidating microbubble destruction and replenishment
ethod forMBF determination, both in experimental
nd clinical studies. Ananda Jayaweera developed a
imple and elegant mathematical model for tissue
utrient flow measurement which has become the
tandard for tissue perfusion measurement in the
eart, brain, kidney, skin, and skeletal muscle. Kevin
as awarded the best Young Investigator Award at
he American College of Cardiology for this work. Jiri
klenar complemented by developing nimble com-
uter algorithms for image analysis that allowed for
he quantification of tissue flow. Using this approach,
ndre Linka demonstrated that subendocardial isch-
mia in the presence of critical coronary stenosis was
ue to reduction in endocardial blood flow velocity
nd not MBV (34).
Once the MBF-flow velocity and MBV could be
ifferentiated, it became possible to identify the re-
ersible perfusion defects that we had originally noted
o be due to a decrease in MBV during vasodilator
tress. Using a novel model, Jayaweera demonstrated
hat in order to maintain a constant hydrostatic
ressure, capillaries distal to a noncritical stenosis
erecruit during pharmacological stress, which forms
he basis for the reversible decrease in MBV and the
eversible perfusion defect seen on any form of myo-
ardial perfusion imaging where a tracer is used (35);
his was subsequently confirmed for 99mtechnetium
estamibi as well (36). Jayaweera demonstrated that
he zero flow coronary pressure thought commonly to
esult from collateral flow occurred from the collapse
f capillaries as perfusion pressure fell during reduced
esting flow. As such, the bottleneck to hyperemic
ow was the capillary bed. Because capillaries are
laced in parallel, less capillaries result in lower flow
eserve such as in MI and hypertension. Elizabeth Le
ater suggested that the capillaries regulate their hy-
rostatic pressure by derecruiting when autoregulation
s exhausted (37).
In an ischemia-reperfusion model of constant cor-
nary flow and microbubble administration directly
nto the coronary arteries, we observed that after
ransiting through the myocardium within a few ceconds at baseline, a proportion of microbubbles
emained in the tissue resulting in persistent myocar-
ial opacification after reperfusion (38). The same
henomenon was seen in patients in the operating
oom after bypass surgery after cold crystalline solution
ompared with warm blood cardioplegia (39).
onathan Lindner investigated this phenomenon in
laus Ley’s laboratory with intravital microscopy us-
ng an exteriorized microcirculation preparation. The
icrobubbles adhered nonspecifically to the adhesion
olecules expressed on leukocytes and endothelial
urface of venules during ischemia and reperfusion
40). This also demonstrated the feasibility of molec-
lar imaging employing microbubbles and ultrasound.
onathan and Liza have conducted numerous studies
n inflammation and angiogenesis using microbubbles
argeted to the endothelial surface. Because of the
onlinear signals emanating from microbubbles, very
ew need to be present within tissue in order to
roduce adequate signal. Jonathan has also studied
keletal muscle microcirculation with microbubbles in
nimal models and in patients presenting with periph-
ral vascular disease (41,42).
Based on the original demonstration that coro-
ary blood volume increased in proportion to the
oronary severity as long as coronary flow was
onstant (noncritical stenosis), we have always been
ntrigued by the possibility of using ultrasound
ontrast to detect CAD at rest. Because the blood
n intramyocardial arterioles comprised only a small
roportion of MBV, microbubble signals from
hese vessels were normally negligible when the
ltrasound beam was fully replenished. However, if
maging was performed using a very short interval
etween destructive ultrasound pulses, the signal
btained was derived only from the vessels that
lled in the short period of time, as neither capil-
aries nor venules had adequate opportunity to fill.
ince forward flow in large intramyocardial vessels
ccurs during diastole, signals on MCE using this
pproach were seen predominantly during diastole.
uring systole, a change in myocardial elastance
aused retrograde displacement of the arteriolar
lood volume into large intramyocardial vessels,
esulting in a small systolic signal on MCE. In the
resence of a stenosis, since arteriolar blood was
arger because of autoregulation, there was greater
etrograde displacement of microbubbles from
maller arterioles and an increase in the systolic
yocardial signal from the large intramyocardial
essels. Because these vessels do not participate in
utoregulation, the diastolic signal remains un-
hanged, and the ratio of systolic to diastolic signal
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216ncreased with more severe stenosis. Wei performed
ainstaking experiments to validate this approach
or CAD detection at rest without the use of any
tressors in both animals (43) and humans (44).
Since capillaries are the bottleneck to hyperemic
ow, factors influencing capillary resistance (mainly
iscosity) could affect hyperemic flow. Se-Joong
im showed that hyperlipidemia reduced flow re-
erve by increasing myocardial vascular resistance
hrough an increase in whole blood viscosity (45).
ian-Ping Bin showed that nitroglycerin increased
icrovascular flow in the ischemic bed by reducing
lood viscosity (46), and also induced hemoglobin
o unload more oxygen in hypoxic tissue. Alcohol
id not change rheology or increase coronary flow
eserve as reported previously.
With the advent of many second- and third-
eneration contrast agents (Optison, Definity,
onovue, Imagent, Sonozoid, Cardiosphere, Ima-
ify), several validation studies were performed in
xperimental studies as well as phase II and III
linical trials. These studies have showed equiva-
ence or even superiority of MCE to radionuclide
yocardial perfusion imaging during pharmacolog-
cal stress in patients with suspected or known
AD (47–49). MCE was equivalent to SPECT
maging in detecting acute coronary syndromes in
atients presenting to the emergency department
ith chest pain (50); MCE imaging demonstrated
ncremental value (51,52) and was superior to the
IMI score at the time of initial emergency depart-
ent presentation (53).
The reason this journey is termed as wondrous isfoil M, Parisi AF. In-vivo prediction
of the transmural extent of experimen- driving pressure on rerst injected microbubbles into the coronary arteries
f dogs at Mass General, I had no idea where the
ourney would lead. It was not even certain whether
icrobubbles would ever be able to cross the lungs.
his journey has taught the intricacies of ultrasound
hysics, microbubble engineering, and the complex
nd fascinating physiology of the coronary micro-
irculation. It has helped design clinical trials, and
xposed investigators to the procedures and policies
f the Food and Drug Administration, Centers for
edicare and Medicaid Services, and the National
nstitutes of Health. It has taught how difficult and
xpensive it is for start-up companies to establish a
ew product, and how reluctant physicians are to
dopt a new technology.
The MCE journey has allowed an excellent
ombination of basic and clinical sciences. I have
een fortunate to be at the center-stage of MCE
esearch supported by outstanding colleagues. A
ignificantly large volume of literature has been
roduced pertaining to basic science, physiology,
athophysiology, and potential clinical applica-
ions of contrast-enhanced echocardiography.
hat is left is to translate it into routine clinical
ractice; this next task ahead of us is perhaps the
ardest to achieve. Nonetheless, this journey has
een immensely fulfilling; to quote the Buddha,
It is better to travel well than to arrive” (54).
eprint requests and correspondence: Dr. Sanjiv Kaul,
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